title: Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.
abstract: This study investigated the role of two fatty acid ethanolamides, the endogenous cannabinoid anandamide and its structural analog oleoylethanolamide in sleep deprivation of human volunteers. Serum and cerebrospinal fluid (CSF) samples were obtained from 20 healthy volunteers before and after a night of sleep deprivation with an interval of about 12 months. We found increased levels of oleoylethanolamide in CSF (P = 0.011) but not in serum (P = 0.068) after 24 h of sleep deprivation. Oleoylethanolamide is an endogenous lipid messenger that is released after neural injury and activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha) with nanomolar potency. Exogenous PPAR-alpha agonists, such as hypolipidemic fibrates and oleoylethanolamide, exert both neuroprotective and neurotrophic effects. Thus, our results suggest that oleoylethanolamide release may represent an endogenous neuroprotective signal during sleep deprivation.
authors.affiliation: Department of Psychiatry and Psychotherapy, University of Cologne, 50924, Cologne, Germany.
authors.forename: Dagmar
authors.initials: D
authors.lastname: Koethe
authors.forename: Daniela
authors.initials: D
authors.lastname: Schreiber
authors.forename: Andrea
authors.initials: A
authors.lastname: Giuffrida
authors.forename: Christian
authors.initials: C
authors.lastname: Mauss
authors.forename: Johannes
authors.initials: J
authors.lastname: Faulhaber
authors.forename: Bernd
authors.initials: B
authors.lastname: Heydenreich
authors.forename: Martin
authors.initials: M
authors.lastname: Hellmich
authors.forename: Rudolf
authors.initials: R
authors.lastname: Graf
authors.forename: Joachim
authors.initials: J
authors.lastname: Klosterkötter
authors.forename: Daniele
authors.initials: D
authors.lastname: Piomelli
authors.forename: F Markus
authors.initials: FM
authors.lastname: Leweke
mesh_terms: D000328:Adult; D001095:Arachidonic Acids / Q000097:blood / Q000134:cerebrospinal fluid* / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000134:cerebrospinal fluid; D002851:Chromatography, High Pressure Liquid; D063388:Endocannabinoids; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000378:metabolism*; D009829:Oleic Acids / Q000097:blood / Q000134:cerebrospinal fluid* / Q000378:metabolism; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism*; D053284:Polyunsaturated Alkamides / Q000097:blood / Q000134:cerebrospinal fluid* / Q000378:metabolism; D012892:Sleep Deprivation / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D055815:Young Adult
chemical_list: D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D018696:Neuroprotective Agents; D009829:Oleic Acids; D047493:PPAR alpha; D053284:Polyunsaturated Alkamides; C488250:oleoylethanolamide; C078814:anandamide